Ixazomib
CAS 1072833-77-2 7 FDA-DMF suppliersSmall Molecule
Overview
Ixazomib is a proteasome inhibitor used in the treatment of multiple myeloma. It is administered as a prodrug and is the first oral proteasome inhibitor developed.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Ixazomib expires 20 Nov 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyHematology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.